These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 37527180

  • 1. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V, Longhitano E, Calabrese V, Casuscelli C, Di Carlo S, Spinella C, Gembillo G, Santoro D.
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [Abstract] [Full Text] [Related]

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF.
    Cochrane Database Syst Rev; 2018 Aug 22; 8(8):CD006023. PubMed ID: 30132304
    [Abstract] [Full Text] [Related]

  • 3. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ.
    Drugs; 2017 Jul 22; 77(11):1155-1186. PubMed ID: 28584909
    [Abstract] [Full Text] [Related]

  • 4. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.
    Am J Kidney Dis; 2009 Oct 22; 54(4):619-37. PubMed ID: 19692157
    [Abstract] [Full Text] [Related]

  • 5. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J.
    J Nephrol; 2020 Jun 22; 33(3):497-508. PubMed ID: 31865608
    [Abstract] [Full Text] [Related]

  • 6. Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality.
    McCullough PA.
    Cardiorenal Med; 2021 Jun 22; 11(3):123-132. PubMed ID: 34120113
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J.
    Nephrol Dial Transplant; 2017 Jan 01; 32(1):111-125. PubMed ID: 27651467
    [Abstract] [Full Text] [Related]

  • 8. Hyperphosphataemia: treatment options.
    Malberti F.
    Drugs; 2013 May 01; 73(7):673-88. PubMed ID: 23625273
    [Abstract] [Full Text] [Related]

  • 9. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N, Angeliki Veroniki A, Thabane L, Busse JW, Akhtar-Danesh N, Iorio A, Cruz Lopes L, Guyatt GH.
    PLoS One; 2017 May 01; 12(3):e0171028. PubMed ID: 28248961
    [Abstract] [Full Text] [Related]

  • 10. Current and potential treatment options for hyperphosphatemia.
    Carfagna F, Del Vecchio L, Pontoriero G, Locatelli F.
    Expert Opin Drug Saf; 2018 Jun 01; 17(6):597-607. PubMed ID: 29783873
    [Abstract] [Full Text] [Related]

  • 11. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]

  • 12. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.
    Nephrol Dial Transplant; 2019 Jul 01; 34(7):1163-1170. PubMed ID: 29846719
    [Abstract] [Full Text] [Related]

  • 13. Use of phosphate binders in chronic kidney disease.
    Ketteler M, Biggar PH.
    Curr Opin Nephrol Hypertens; 2013 Jul 01; 22(4):413-20. PubMed ID: 23736841
    [Abstract] [Full Text] [Related]

  • 14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jul 01; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 15. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar 01; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 16. Osteo-renal regulation of systemic phosphate metabolism.
    Razzaque MS.
    IUBMB Life; 2011 Apr 01; 63(4):240-7. PubMed ID: 21438115
    [Abstract] [Full Text] [Related]

  • 17. Phosphate binders in chronic kidney disease: a systematic review of recent data.
    Floege J.
    J Nephrol; 2016 Jun 01; 29(3):329-340. PubMed ID: 26800972
    [Abstract] [Full Text] [Related]

  • 18. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, Buemi M.
    Int J Nephrol Renovasc Dis; 2016 Jun 01; 9():11-9. PubMed ID: 26893577
    [Abstract] [Full Text] [Related]

  • 19. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L, Liu A, Xu G.
    Ren Fail; 2021 Dec 01; 43(1):1378-1393. PubMed ID: 34602015
    [Abstract] [Full Text] [Related]

  • 20. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M, Papachristou E, Goumenos DS.
    Expert Opin Pharmacother; 2013 Dec 01; 14(18):2521-32. PubMed ID: 24215605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.